申请人:RaQualia Pharma Inc.
公开号:US07718809B2
公开(公告)日:2010-05-18
This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, B, X, R1, R2, R3, R4, R5 and R6, R7, R8 and R9 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited to, as gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of Helicobacter pylori, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma.
本发明涉及公式(I)的化合物或其药学上可接受的盐,其中:A、B、X、R1、R2、R3、R4、R5和R6、R7、R8和R9各自如本文所述或其药学上可接受的盐,并且包含这种化合物的组合物以及在治疗由酸泵拮抗活性介导的疾病中使用这种化合物,例如但不限于胃肠道疾病、胃食管疾病、胃食管反流病(GERD)、消化性溃疡、胃溃疡、十二指肠溃疡、N
SAID诱导性溃疡、胃炎、幽门螺杆菌感染、消化不良、功能性消化不良、佐林格-埃里森综合征、非侵蚀性反流病(NERD)、内脏疼痛、心灼热、恶心、食管炎、吞咽困难、过度流涎、气道疾病或哮喘。